Osteoporosis: Should there be a screening programme in Hong Kong?

Hong Kong Medical Journal

Volumn 8, Issue 4, 2002, Pages 270-277

  Hui, Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Mass screening; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; HORMONE; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

BONE MASS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE PREDISPOSITION; ECHOGRAPHY; EVIDENCE BASED MEDICINE; HONG KONG; HORMONE SUBSTITUTION; HUMAN; MASS SCREENING; MORBIDITY; MORTALITY; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PATIENT SELECTION; PREVALENCE; REVIEW; RISK FACTOR; WORLD HEALTH ORGANIZATION; ECONOMICS; FEMALE; MALE; PRACTICE GUIDELINE; STANDARD;

COST-BENEFIT ANALYSIS; FEMALE; HONG KONG; HUMAN; MALE; MASS SCREENING; OSTEOPOROSIS; PRACTICE GUIDELINES; WORLD HEALTH ORGANIZATION; HUMANS;

EID: 0036023235     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis
2. The necessity of a managed care approach for osteoporosis
3. Clinical management guidelines for osteoporosis in Hong Kong
4. The prevalence of osteoporosis in the Hong Kong Chinese female population
5. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
6. Hip fracture in Asia - Trends, risk factors and prevention
7. Normal ranges for vertebral height ratios and prevalence of vertebral fracture in Hong Kong Chinese: A comparison with American Caucasians
8. Consequences of alterations in bone remodeling
9. Bone status and fracture rates in two regions of Yugoslavia
10. Osteoporosis and epidemiology of fractures in Croatia. An international comparison
11. Dietary calcium and bone density among middle-aged and elderly women in China
12. Bone mineral acquisition during childhood and adolescence: Physical exercise as a preventive measure
13. Risk factors for hip fracture in white women
14. Epidemiology and prevention of osteoporosis in urbanized Asian populations
15. Short-term and long-term fracture prediction by bone mass measurements: A prospective study
16. The epidemiology of osteoporosis. The oriental perspective in a world context
17. Rapid postmenopausal loss of total body and regional bone mass in normal southern Chinese females in Hong Kong
18. Evaluation of a new calcaneal quantitative ultrasound system and determination of normative ultrasound values in southern Chinese women
19. Quantitative ultrasound and symptomatic vertebral fracture risk in Chinese women
20. Can the WHO criteria for diagnosing osteoporosis be applied to calcaneal quantitative ultrasound?
21. Quantitative ultrasound: An indicator of osteoporosis in perimenopausal women
22. Quantitative ultrasound in postmenopausal osteoporosis
23. Precision and sensitivity of dual-energy x-ray absorptiometry in spinal osteoporosis
24. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial
25. Treatment of postmenopausal osteoporosis with transdermal estrogen
26. Estrogen replacement therapy and fractures in older women
27. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS)
28. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial
29. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
30. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
31. Evidence-based medicine and osteoporosis: A comparison of fracture risk reduction data from osteoporosis randomised clinical trials
32. Treatment of postmenopausal osteoporosis
33. The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: A randomized placebo-controlled study
34. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
35. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
36. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
37. Effect of risedronate on the risk of hip fracture in elderly women
38. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: A prospective study
39. Effect of calcitonin on vertebral and other fractures
40. The effects of calcium supplementation and exercise on bone density in elderly Chinese women
41. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial
42. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women
43. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
44. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
45. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
46. Osteoporosis - Is it really preventable?
47. The effects of different dosages of oestrogen on the bone mineral density of postmenopausal Hong Kong Chinese women: Randomised controlled trial
48. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
49. Screening and treatment in the elderly to reduce osteoporotic fracture risk